Existing backer WuXi Pharmatech Healthcare Fund returned for a series B round that will enable Tennor to move its antibiotics into late-stage development.
China-based antibiotics developer Tennor Therapeutics picked up $25m in series A capital on Monday from a consortium including R&D services provider WuXi PharmaTech’s Healthcare Fund I.
Venture capital firm Northern Light Venture Capital led the round, while Frontline BioVentures, Oriza Venture Capital and Relativity Healthcare Fund also contributed cash.
Founded in 2013, Tennor is working on a range of antibiotics. Its lead candidate, TNP-2092, is a pill aimed at digestive diseases, primarily those linked to Helicobacter pylori, a bacterium responsible…
